Cholesterol-Lowering Agents: Statins—For Everyone?

Hadjiphilippou, Savvas; Ray, Kausik K.

doi:10.1161/circresaha.118.313245

Cited by 49

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Cholesterol-Lowering Agents: Statins—For Everyone?

Hadjiphilippou, Savvas, Ray, Kausik K.·2019·Circulation Research

DOI 10.1161/circresaha.118.313245

Open this paper in CoChat — free account

Abstract

Cardiovascular disease (CVD) remains the leading cause of death worldwide. To date, decades of research has established LDL-C (low-density lipoprotein cholesterol) as a causal factor in the development of atherosclerotic CVD. Statin therapy, supported by a broad evidence base, has demonstrated its superior efficacy in reducing LDL-C and subsequent cardiovascular risk. It therefore currently forms the mainstay of lipid-lowering therapy as recommended by international guidelines. Statin therapy is indicated in the secondary prevention of atherosclerotic CVD, as well as genetic causes of dyslipidemia (such as familial hypercholesterolemia). Although this strategy targets those most at risk, it merely addresses those most susceptible and does not account for the fact that most cardiovascular events occur in those at moderate to low risk. In addition, there is evidence for use in primary prevention such as in those with diabetes mellitus, chronic kidney disease, and high risk of future atherosclerotic CVD as determined by risk prediction calculators. Risk prediction tools, however, are far from perfect and do not accurately account for those at low short-term but high lifelong risk. Considering the log-linear relationship between LDL-C reductions and reductions in risk of atherosclerotic CVD, even in those at very low risk of future events, a clinical question posed is can we and should we shift the entire risk distribution by treating everyone? The present review discusses these issues in more detail outlining arguments for and against each approach.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/circresaha.118.313245

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887
Explaining the decrease in U.S. deaths from coronary disease, 1980–2000
Ford, E. S., Ajani, U. A., Croft, J. B., Critchley, J. A., Labarthe, D. R., Kottke, T. E., Giles, W. H., & Capewell, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa053935 · Cited by 2,757
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Self-citation
European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)
De Backer, G. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00347-6 · Cited by 2,251
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857

Show all 25 references

Research works printed but not linked: 73

10.1016/S0140-6736(04)17018-9 · DOI · Paper page
10.2183/pjab.86.484 · DOI
10.1016/0014-5793(76)80996–9 · DOI
10.1016/j.atherosclerosissup.2004.08.027 · DOI
10.1056/NEJM199511163332001 · DOI · Paper page
10.1016/S0140-6736(02)09327-3 · DOI · Paper page
10.1056/NEJMoa0807646 · DOI · Paper page
10.1093/eurheartj/ehx144 · DOI · Paper page
10.1016/S0140-6736(12)60367-5 · DOI · Paper page
10.1177/2047487316653709 · DOI
10.1093/eurheartj/ehv043 · DOI · Paper page
10.1093/eurheartj/ehy182 · DOI · Paper page
10.1016/j.jacc.2013.11.002 · DOI · Paper page
10.1056/NEJM199811053391902 · DOI · Paper page
10.1056/NEJM199610033351401 · DOI · Paper page
10.1001/jama.285.13.1711 · DOI · Paper page
10.1001/jama.294.19.2437 · DOI · Paper page
10.1161/CIRCULATIONAHA.117.032615 · DOI
10.1016/j.jacc.2004.07.053 · DOI
10.1016/S0140-6736(05)67394-1 · DOI · Paper page
10.1016/S0140-6736(10)61350–5 · DOI · Paper page
10.1093/eurheartj/eht273 · DOI · Paper page
10.1016/j.atherosclerosis.2015.09.021 · DOI
10.1136/bmj.303.6807.893 · DOI · Paper page
10.1001/archinte.158.6.655 · DOI
10.1161/CIRCULATIONAHA.115.018383 · DOI
10.1161/CIRCULATIONAHA.116.022335 · DOI
10.7326/M17-0681 · DOI
10.1136/hrt.2007.140905 · DOI
10.1001/jama.279.20.1615 · DOI · Paper page
Chou, R, Dana, T, Blazina, I, Daeges, M, Bougatsos, C, Grusing, S, Jeanne, TL. Statin use for the prevention of cardiovascular disease in adults: a systematic review for the U.S. Preventive Services Task Force [Internet]. Rockville, MD: Agency for Healthcare Research and Quality (US); November 2016.
10.1002/14651858.CD004816.pub5 · DOI · Paper page
10.1093/ije/14.1.32 · DOI · Paper page
10.1016/S0140-6736(10)60674–5 · DOI · Paper page
10.1056/NEJMoa041365 · DOI
10.1093/eurheartj/ehx209 · DOI
10.1016/S0140-6736(11)60739-3 · DOI · Paper page
10.1056/NEJMoa043545 · DOI · Paper page
10.1161/01.CIR.100.10.1134 · DOI · Paper page
10.2337/diab.23.2.105 · DOI · Paper page
10.2337/diacare.16.2.434 · DOI · Paper page
10.1016/0735-1097(89)90053-3 · DOI
10.1016/S0140-6736(10)60484–9 · DOI · Paper page
10.1016/S0140-6736(04)16895-5 · DOI · Paper page
10.1016/S0140-6736(08)60104-X · DOI · Paper page
10.2337/dc05-2415 · DOI · Paper page
10.1111/j.1076-7460.2003.02000.x · DOI
10.1161/CIRCULATIONAHA.117.028271 · DOI
10.1016/j.amjcard.2005.09.142 · DOI
10.1016/j.amjcard.2004.01.039 · DOI
10.1093/eurheartj/ehv072 · DOI · Paper page
10.1136/bmj.303.6797.276 · DOI
10.1371/journal.pone.0029849 · DOI
10.1016/j.cjca.2010.12.024 · DOI
10.1007/s11606-008-0636-7 · DOI
10.1016/S0140-6736(17)31075-9 · DOI · Paper page
10.1001/jama.2016.3608 · DOI · Paper page
10.7326/0003-4819-158-7-201304020-00004 · DOI · Paper page
10.1016/j.ahj.2013.06.004 · DOI · Paper page
10.1161/CIRCULATIONAHA.111.055269 · DOI
10.1016/j.jacc.2010.10.047 · DOI · Paper page
10.1016/S2213-8587(14)70173-1 · DOI · Paper page
10.1161/CIRCULATIONAHA.107.699579 · DOI · Paper page
10.1016/j.jacc.2016.02.055 · DOI
10.7326/M14-1281 · DOI
10.1001/jama.2014.2632 · DOI
10.1161/CIRCULATIONAHA.110.986349 · DOI
10.7326/0003-4819-150-4-200902170-00005 · DOI
10.1161/CIRCULATIONAHA.117.027067 · DOI
10.1136/bmj.38993.731725.BE · DOI
10.1016/j.amjcard.2009.09.025 · DOI
10.1016/j.jacc.2009.08.035 · DOI
10.1016/j.jacc.2009.10.005 · DOI

Sorted by citations

Endothelial force sensing signals to parenchymal cells to regulate bile and plasma lipids
Lichtenstein, L., Cheng, C. W., Bajarwan, M., Evans, E. L., Gaunt, H. J., Bartoli, F., Chuntharpursat-Bon, E., Patel, S., Konstantinou, C., Futers, T. S., et al. (2024) · Science Advances · doi:10.1126/sciadv.adq3075 · Cited by 15
ABCC4 impairs the clearance of plasma LDL cholesterol through suppressing LDLR expression in the liver
Chen, J., Huang, H., Chen, C., Xia, G., Huang, H., Xiong, Y., Luo, P., Chen, Y., Li, J., Wen, L., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08818-x · Cited by 1

See all 49

Authors: Hadjiphilippou, S., & Ray, K. K.
Venue: Circulation Research
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2019-02
Volume: 124
Issue: 3
Pages: 354-363
ISSN: 0009-7330
1524-4571
DOI: 10.1161/circresaha.118.313245
Cited by: 49
References: 25
Language: en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page: CoChat. (2026). Citation check: Cholesterol-Lowering Agents: Statins—For Everyone? https://app.cochat.ai/papers/10.1161/circresaha.118.313245
The paper: Hadjiphilippou, S., & Ray, K. K. (2019). Cholesterol-Lowering Agents: Statins—For Everyone? Circulation Research. https://doi.org/10.1161/circresaha.118.313245

Cholesterol-Lowering Agents: Statins—For Everyone?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

How to cite